We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PLBL:NASDAQPolibeli Group Ltd Analysis

Data as of 2026-06-13 - not real-time

$7.75

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Polibeli Group Ltd (PLBL) is trading at $7.75, barely below its 30‑day resistance of $8.80 and well above the 20‑day SMA ($6.61) but still under the 50‑day SMA ($7.10), indicating a mixed short‑term price signal. The technical picture shows a bullish MACD histogram (+0.099) while the overall trend is flagged as bearish, and the RSI at 62 points suggests the stock is approaching overbought territory. Volatility is extreme at 93 % over the past month, with a max drawdown of 55 % and a negative beta (‑0.18), underscoring heightened market sensitivity. Fundamentally, revenue has surged 61 % year‑over‑year, yet gross margin sits at just 7 % and operating margin is deeply negative (‑25 %), leading to a trailing EPS of ‑0.02 and a price‑to‑sales ratio above 100×. The balance sheet shows modest cash ($3.1 M) against low debt, but negative book value (‑$0.124 per share) and a PB ratio of ‑62.5 render valuation metrics meaningless. The combination of aggressive growth, poor profitability, and an extreme “Greed” market sentiment creates a precarious risk‑reward profile.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • price near resistance with bearish trend flag
  • extreme volatility and large recent drawdown
  • overvaluation indicated by price‑to‑sales >100×

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • strong revenue growth potential
  • persistent operating losses and negative margins
  • uncertain path to profitability

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • digital supply‑chain platform could capture market share
  • need for turnaround in earnings and balance sheet health
  • high valuation risk balanced by growth narrative

Key Metrics & Analysis

Financial Health

Revenue Growth61.10%
Profit Margin-22.60%
ROA-24.50%
P/B Ratio-62.5
Op. Cash Flow$-6354919
Free Cash Flow$-199612

Technical Analysis

TrendBearish
RSI61.9
Support$5.21
Resistance$8.80
MA 20$6.61
MA 50$7.10
MA 200$8.71
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta-0.18
Volatility93.36%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.